My mistake. I forgot it was a 1-for-7 RS and not a 1-for-10 RS like Citibank.
However, the lessons learned from Citibank still apply here. Lpath is still on the OTC. Simply inflating the price through a RS doesn't move it to the NASDAQ. They hope it will help meet the requirements, but we're not there yet. But I hope someday that will eventually happen.
In the meantime, the RS is exactly as you stated, it is only to sure up its price on an existing exchange (OTC).
It's all about bucks, kid. The rest is conversation.